HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
HALO fundamentals
Halozyme Therapeutics (HALO) released its earnings on Nov 3, 2025: revenue was 354.00M (YoY +22.07%), beat estimates; EPS was 1.72 (YoY +35.43%), beat estimates.
Revenue / YoY
354.00M
+22.07%
EPS / YoY
1.72
+35.43%
Report date
Nov 3, 2025
HALO Earnings Call Summary for Q3,2025
- Revenue Surge: Q3 2025 royalty revenue up 52% YoY to $236 million, total revenue $354 million (+22% YoY). Full-year 2025 guidance raised to $1.3-$1.375 billion.
- Blockbuster Growth: Darzalex sales $3.7 billion (+20% YoY), Vyvgart $1.13 billion (+96% YoY), Fesgo conversion rate 51%.
- Strategic Expansion: Electrovive acquisition to unlock $2+ billion pipeline via HyperCon technology; 2026 first-in-human trials for blockbuster products.
- Financial Strength: Non-GAAP EPS $1.72 (vs. $1.27 YoY), cash balance $702 million, net debt/EBITDA 0.9x. 2025 free cash flow to support ~$500 million buybacks.
- Pipeline Momentum: Ocrevus subcutaneous adoption +75% to 12,500 patients; Vyvgart CIDP 85% IVIG switch rate; Tecentriq Hybrisa targeting $4.5 billion by 2028.
EPS
Revenue
Revenue & Expenses
HALO has released its 2025 Q3 earnings report, with revenue of 354.26M, reflecting a YoY change of 22.12%, and net profit of 175.22M, showing a YoY change of 27.89%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.
Key Indicators
Halozyme Therapeutics (HALO) key financial stats and ratios, covering profitability, financial health, and leverage.
Halozyme Therapeutics (HALO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Halozyme Therapeutics (HALO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Halozyme Therapeutics (HALO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What guidance did Halozyme Therapeutics's management provide for the next earnings period?What were the key takeaways from Halozyme Therapeutics’s earnings call?Did Halozyme Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Halozyme Therapeutics's earnings call?What is Halozyme Therapeutics's gross profit margin?What is the revenue and EPS growth rate for Halozyme Therapeutics year over year?What is Halozyme Therapeutics's latest dividend and current dividend yield?What does Halozyme Therapeutics do and what are its main business segments?
